Increasing sensitivity to radiotherapy and chemotherapy by using novel biological agents that alter the tumor microenvironment

Current Molecular Medicine
E T Shinohara, A Maity

Abstract

Sensitivity to radiation and chemotherapy can be influenced by factors extrinsic to the cancer cell. For example, severely hypoxic cells require 2-3 times the radiation dose as do well-oxygenated cells to achieve similar cell killing. Apart from the tumor cells, neighboring cells such as endothelial cells may influence radiosensitivity. Irradiation can lead to expression of molecules that may increase radio/chemoresistance, for example vascular endothelial growth factor (VEGF), a secreted protein that regulates angiogenesis, or hypoxia inducible factor-1 alpha (HIF-1 alpha), a master transcription factor that regulates gene expression in hypoxia. Hence, response to cytotoxic therapy may be improved by modulating the tumor microenvironment (TME). Several agents in clinical use may do this. Some of these target vasculature, either directly or indirectly by disrupting VEGF and/or HIF-1 signaling. Many of these agents have been shown to increase radio/chemosensitivity in preclinical models. A confounding factor in terms of radiosensitization is the variable effect of these drugs on tumor oxygenation. Some of these agents ablate the vasculature, thereby increasing hypoxia. Others may normalize tumor vasculature, leading to increased...Continue Reading

Citations

Sep 21, 2011·Proceedings of the National Academy of Sciences of the United States of America·Naokazu ChibaShyamala Maheswaran
Jan 14, 2012·Cancer Biotherapy & Radiopharmaceuticals·Kwan-Hwa ChiShang-Jyh Kao
Jul 19, 2012·Endocrine-related Cancer·Nicola M BougenJo K Perry
Apr 9, 2011·International Journal of Radiation Biology·Keng-Li LanSang-Hue Yen
Oct 13, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Takahiro NakajimaKazuhiro Yasufuku
Nov 28, 2012·Critical Reviews in Oncology/hematology·Céline ClémensonEric Deutsch
Apr 30, 2013·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Nathalie CrokartVéronique Préat
Mar 6, 2012·Nanomedicine·Hasmik AgadjanianLali K Medina-Kauwe
Jul 25, 2015·Chemical Communications : Chem Comm·Sisi WangZhen Shen
Jan 14, 2011·The Journal of International Medical Research·X-H WuS-H Zhou
Dec 9, 2017·Organic & Biomolecular Chemistry·Xingye YangMinyong Li
May 13, 2011·American Journal of Physiology. Cell Physiology·Annarosa Arcangeli
Oct 16, 2018·Molecular Medicine Reports·Zhichao FuFengmei Wang
Mar 24, 2020·Journal of Cellular and Molecular Medicine·Xiao LeiBaolin Qu
Oct 24, 2018·Journal of Biomedical Optics·Brian W Pogue, Brian C Wilson
Dec 19, 2009·Journal of Neuro-oncology·Hamidreza AliabadiJohn H Sampson
Sep 6, 2017·Frontiers in Oncology·Emma C FieldsSarah M Temkin
Oct 15, 2014·Molecular Cancer Therapeutics·Seon-Yong YeomChaehwa Park
Jun 19, 2012·Chemical Reviews·Yuming YangFuyou Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.